$OM
Outset Medical, Inc.

2024 Q2 Form 10-Q Financial Statement

#000095017024055981 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $27.39M $28.17M
YoY Change -24.01% -15.83%
Cost Of Revenue $17.61M $19.95M
YoY Change -37.87% -26.21%
Gross Profit $9.782M $8.215M
YoY Change 26.99% 27.8%
Gross Profit Margin 35.72% 29.16%
Selling, General & Admin $30.81M $32.49M
YoY Change -15.06% -10.04%
% of Gross Profit 314.99% 395.52%
Research & Development $9.734M $12.64M
YoY Change -34.7% -8.4%
% of Gross Profit 99.51% 153.8%
Depreciation & Amortization $1.471M $1.460M
YoY Change -2.84% 5.49%
% of Gross Profit 15.04% 17.77%
Operating Expenses $40.55M $45.13M
YoY Change -20.78% -9.59%
Operating Profit -$30.76M -$36.91M
YoY Change -29.24% -15.12%
Interest Expense $6.010M $5.968M
YoY Change 93.68% 102.86%
% of Operating Profit
Other Income/Expense, Net $2.471M $3.098M
YoY Change -7.38% 16.99%
Pretax Income -$34.30M -$39.78M
YoY Change -21.88% -9.13%
Income Tax $151.0K $162.0K
% Of Pretax Income
Net Earnings -$34.45M -$39.90M
YoY Change -21.78% -9.32%
Net Earnings / Revenue -125.8% -141.65%
Basic Earnings Per Share -$0.66 -$0.78
Diluted Earnings Per Share -$0.66 -$0.78
COMMON SHARES
Basic Shares Outstanding 51.72M 50.51M
Diluted Shares Outstanding 51.88K 50.90K

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $168.0M $190.1M
YoY Change -4.12% 53.52%
Cash & Equivalents $37.86M $32.18M
Short-Term Investments $130.1M $157.9M
Other Short-Term Assets $4.569M $6.155M
YoY Change -12.4% 2.33%
Inventory $61.60M $55.84M
Prepaid Expenses
Receivables $34.12M $36.48M
Other Receivables $0.00 $0.00
Total Short-Term Assets $295.1M $325.4M
YoY Change -4.61% -3.52%
LONG-TERM ASSETS
Property, Plant & Equipment $10.87M $11.95M
YoY Change -25.21% -21.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $520.0K $540.0K
YoY Change -53.9% -49.39%
Total Long-Term Assets $19.40M $20.85M
YoY Change -22.53% -17.88%
TOTAL ASSETS
Total Short-Term Assets $295.1M $325.4M
Total Long-Term Assets $19.40M $20.85M
Total Assets $314.5M $346.2M
YoY Change -5.95% -4.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.255M $6.773M
YoY Change 137.03% 240.69%
Accrued Expenses $21.77M $25.83M
YoY Change -29.42% -7.6%
Deferred Revenue $13.11M $12.84M
YoY Change 20.77% 42.06%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $43.43M $50.67M
YoY Change -11.04% 14.46%
LONG-TERM LIABILITIES
Long-Term Debt $197.0M $196.8M
YoY Change 103.87% 103.99%
Other Long-Term Liabilities $5.508M $5.559M
YoY Change -6.34% -1.28%
Total Long-Term Liabilities $197.0M $196.8M
YoY Change 103.87% 103.99%
TOTAL LIABILITIES
Total Short-Term Liabilities $43.43M $50.67M
Total Long-Term Liabilities $197.0M $196.8M
Total Liabilities $245.9M $253.0M
YoY Change 62.51% 72.87%
SHAREHOLDERS EQUITY
Retained Earnings -$1.000B -$1.000B
YoY Change 14.03% 20.06%
Common Stock $1.105B $1.095B
YoY Change 4.2% 4.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $68.60M $93.20M
YoY Change
Total Liabilities & Shareholders Equity $314.5M $346.2M
YoY Change -5.95% -4.53%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$34.45M -$39.90M
YoY Change -21.78% -9.32%
Depreciation, Depletion And Amortization $1.471M $1.460M
YoY Change -2.84% 5.49%
Cash From Operating Activities -$33.34M -$45.91M
YoY Change 18.31% 2.58%
INVESTING ACTIVITIES
Capital Expenditures $120.0K $354.0K
YoY Change -84.91% -56.3%
Acquisitions
YoY Change
Other Investing Activities $39.06M -$58.68M
YoY Change 39.76% -1799.3%
Cash From Investing Activities $38.94M -$59.03M
YoY Change 43.41% -2333.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 77.00K 68.61M
YoY Change -92.62% 1200.17%
NET CHANGE
Cash From Operating Activities -33.34M -45.91M
Cash From Investing Activities 38.94M -59.03M
Cash From Financing Activities 77.00K 68.61M
Net Change In Cash 5.683M -36.33M
YoY Change 28315.0% -1.37%
FREE CASH FLOW
Cash From Operating Activities -$33.34M -$45.91M
Capital Expenditures $120.0K $354.0K
Free Cash Flow -$33.46M -$46.27M
YoY Change 15.48% 1.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001484612
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-39513
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Outset Medical, Inc.
CY2023Q1 us-gaap Gross Profit
GrossProfit
6428000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12635000
CY2024Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
3200000
CY2023Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
3712000
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-0514392
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
3052 Orchard Dr.
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Jose
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
95134
CY2024Q1 dei City Area Code
CityAreaCode
669
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
231-8200
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2024Q1 dei Trading Symbol
TradingSymbol
OM
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
51722375
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32176000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68509000
CY2024Q1 us-gaap Short Term Investments
ShortTermInvestments
194743000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
134815000
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
36478000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
32980000
CY2024Q1 us-gaap Inventory Net
InventoryNet
55839000
CY2023Q4 us-gaap Inventory Net
InventoryNet
49215000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6155000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5700000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
325391000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
291219000
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3329000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3329000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11953000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13273000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5029000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5375000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
540000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
605000
CY2024Q1 us-gaap Assets
Assets
346242000
CY2023Q4 us-gaap Assets
Assets
313801000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
6773000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5827000
CY2024Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
14248000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
19005000
CY2024Q1 om Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
11968000
CY2023Q4 om Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
13459000
CY2024Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
12839000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11727000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1642000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1593000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
50670000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
55323000
CY2024Q1 om Accrued Interest Noncurrent
AccruedInterestNoncurrent
1319000
CY2023Q4 om Accrued Interest Noncurrent
AccruedInterestNoncurrent
896000
CY2024Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
186000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
101000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4054000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4482000
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
196813000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
130113000
CY2024Q1 us-gaap Liabilities
Liabilities
253042000
CY2023Q4 us-gaap Liabilities
Liabilities
190915000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51702000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51702000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50317000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50317000
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
52000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
50000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1095097000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1084515000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-258000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
68000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1001691000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-961747000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
93200000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
122886000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
346242000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
313801000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
28168000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33467000
CY2024Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
19953000
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
27039000
CY2024Q1 us-gaap Gross Profit
GrossProfit
8215000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13793000
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1460000
CY2024Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
21048000
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
24333000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11444000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11787000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
45127000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
49913000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-36912000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-43485000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3098000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2648000
CY2024Q1 us-gaap Interest Expense
InterestExpense
5968000
CY2023Q1 us-gaap Interest Expense
InterestExpense
2942000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39782000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43779000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
162000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
192000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-39944000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-43971000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.78
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.78
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.9
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.9
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50901
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50901
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48783
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48783
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-39944000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-43971000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-326000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
451000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40270000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43520000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
122886000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2080000
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
295000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8203000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-326000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-39944000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
93200000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
245990000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4594000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
684000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8538000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
451000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-43971000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
216286000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-39944000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-43971000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
8203000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
8538000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-36836000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
71838000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
76533000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
35505000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39697000
CY2024Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
256000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1384000
CY2024Q1 om Non Cash Lease Expense
NonCashLeaseExpense
346000
CY2023Q1 om Non Cash Lease Expense
NonCashLeaseExpense
295000
CY2024Q1 om Non Cash Interest Expense
NonCashInterestExpense
607000
CY2023Q1 om Non Cash Interest Expense
NonCashInterestExpense
463000
CY2024Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1577000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1550000
CY2024Q1 om Provision For Inventories
ProvisionForInventories
450000
CY2023Q1 om Provision For Inventories
ProvisionForInventories
870000
CY2024Q1 om Other Non Cash Items
OtherNonCashItems
-1000
CY2023Q1 om Other Non Cash Items
OtherNonCashItems
-18000
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3497000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6224000
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6981000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-2873000
CY2024Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
400000
CY2023Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-569000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
945000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1475000
CY2024Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-4462000
CY2023Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-7100000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1367000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2337000
CY2024Q1 om Increase Decrease In Accrued Warranty Liability
IncreaseDecreaseInAccruedWarrantyLiability
-512000
CY2023Q1 om Increase Decrease In Accrued Warranty Liability
IncreaseDecreaseInAccruedWarrantyLiability
-51000
CY2024Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1197000
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
341000
CY2024Q1 om Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-379000
CY2023Q1 om Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-313000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45912000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44756000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
354000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
810000
CY2024Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
98652000
CY2023Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
68147000
CY2024Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
39975000
CY2023Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
71600000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-59031000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2643000
CY2024Q1 om Proceeds From Stock Options Exercised And Employee Stock Purchase Plan Purchases
ProceedsFromStockOptionsExercisedAndEmployeeStockPurchasePlanPurchases
2086000
CY2023Q1 om Proceeds From Stock Options Exercised And Employee Stock Purchase Plan Purchases
ProceedsFromStockOptionsExercisedAndEmployeeStockPurchasePlanPurchases
5277000
CY2024Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
66524000
CY2023Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
68610000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5277000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-36333000
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
201000
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
4924000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
2479000
CY2024Q1 om Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
379000
CY2023Q1 om Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
313000
CY2024Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
37000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
55000
CY2024Q1 om Transfer Of Inventories To Property And Equipment
TransferOfInventoriesToPropertyAndEquipment
93000
CY2023Q1 om Transfer Of Inventories To Property And Equipment
TransferOfInventoriesToPropertyAndEquipment
0
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-39900000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-44000000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1000000000
CY2024Q1 om Cash Cash Equivalents Restricted Cash And Short Term Investments
CashCashEquivalentsRestrictedCashAndShortTermInvestments
230200000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
28168000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33467000
CY2024Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
13000000
CY2024Q1 om Revenue Performance Obligation1
RevenuePerformanceObligation1
12800000
CY2024Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2024Q1 om Revenue Performance Obligation1
RevenuePerformanceObligation1
200000
CY2024Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
5600000
CY2024Q1 om Debt Securities Available For Sale Remaining Contractual Maturities Period
DebtSecuritiesAvailableForSaleRemainingContractualMaturitiesPeriod
one month to fifteen months
CY2024Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
157890000
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
296000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
64877000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
74000
CY2024Q1 us-gaap Restricted Cash
RestrictedCash
3300000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
3300000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32176000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36386000
CY2024Q1 us-gaap Restricted Cash
RestrictedCash
3329000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
3311000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35505000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39697000
CY2024Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
22322000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
18706000
CY2024Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
11693000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
8728000
CY2024Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
21824000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
21781000
CY2024Q1 us-gaap Inventory Net
InventoryNet
55839000
CY2023Q4 us-gaap Inventory Net
InventoryNet
49215000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8538000
CY2024Q1 om Accrued Inventory Current
AccruedInventoryCurrent
3400000
CY2023Q4 om Accrued Inventory Current
AccruedInventoryCurrent
3395000
CY2024Q1 om Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
530000
CY2023Q4 om Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
1050000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1257000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1153000
CY2024Q1 us-gaap Accrued Exchange Fee Rebate Current
AccruedExchangeFeeRebateCurrent
1555000
CY2023Q4 us-gaap Accrued Exchange Fee Rebate Current
AccruedExchangeFeeRebateCurrent
2100000
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5226000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5761000
CY2024Q1 om Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
11968000
CY2023Q4 om Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
13459000
CY2024Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
200000000
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
133476000
CY2024Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
3187000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
3363000
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
196813000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
130113000
CY2024Q1 om Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Percentage Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageVestedInPeriod
0.50
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8203000
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6648000
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5258000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Restructuring Charges
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges
854000
CY2024Q1 us-gaap Restructuring Charges
RestructuringCharges
2956000
CY2024Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
781000
CY2024Q1 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Restructuring Charges
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges
3029000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-24-055981-index-headers.html Edgar Link pending
0000950170-24-055981-index.html Edgar Link pending
0000950170-24-055981.txt Edgar Link pending
0000950170-24-055981-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
om-20240331.htm Edgar Link pending
om-20240331.xsd Edgar Link pending
om-ex10_2.htm Edgar Link pending
om-ex31_1.htm Edgar Link pending
om-ex31_2.htm Edgar Link pending
om-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
om-20240331_htm.xml Edgar Link completed
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending